BOLALARDA COVID-19 DAN KEYIN RIVOJLANGAN YUVENIL IDIOPATIK ARTRITNING KLINIK-LABORATOR, IMMUNOLOGIK VA ULTRATOVUSH XUSUSIYATLARI
DOI:
https://doi.org/10.5281/zenodo.23642820Keywords:
yuvenil idiopatik artrit, COVID-19, bolalar, JADAS-27, IL-6, sinovit, ultratovush tekshiruvi, energetik Doppler, US7, GLOESS, immunologik markerlarAbstract
Dolzarbligi. Bolalarda COVID-19 koronavirus infeksiyasidan keyin rivojlangan yuvenil idiopatik artritning (YuIA) xususiyatlarini aniqlash infeksiyadan keyingi davrda immun regulyatsiyasi va yallig’lanish faolligining mumkin bo’lgan o’zgarishlari bilan bog’liq holda qiziqish uyg’otadi. Klinik belgilar, laborator ko’rsatkichlar, immunologik markerlar va ultratovush tekshiruvi (UTT) natijalarini kompleks baholash kasallikni to’liqroq tavsiflash va bolalardagi mumkin bo’lgan xavflarni aniqlash imkonini beradi. Tadqiqot maqsadi. Bolalarda COVID-19 koronavirus infeksiyasidan keyin rivojlangan YuIAning klinik-laborator, immunologik va ultratovush xususiyatlarini aniqlash. Material va usullar. YuIA bilan kasallangan 80 nafar bola tekshirildi: kasallik COVID-19 dan 2–12 oy o’tgach rivojlangan 40 nafar bemor (asosiy guruh) va kasallik boshlanishining SARS-CoV-2 infeksiyasi bilan aloqasi aniqlanmagan 40 nafar bemor (taqqoslash guruhi). Bolalarda klinik belgilar, JADAS-27 bo’yicha kasallik faolligi, CHAQ bo’yicha funksional buzilishlar, umumiy qon tahlili, tizimli yallig’lanish ko’rsatkichlari, revmatologik va immunologik markerlar, interleykin-6 (IL-6) darajasi hamda bo’g’imlar UTT natijalari baholandi. UTT natijalari asosida US7 va GLOESS kompozit indekslari hisoblandi. Xulosa. COVID-19 dan keyin YuIA rivojlangan tekshirilgan bolalarda kasallikning yuqoriroq yallig’lanish faolligiga mos keluvchi klinik, laborator, immunologik va ultratovush xususiyatlari kompleksi aniqlandi. Ultratovush indekslari klinik faollik va yallig’lanish ko’rsatkichlari bilan o’rtacha va kuchli korrelyatsiyalarni ko’rsatdi.References
1. McGonagle, D., Sharif, K., O’Regan, A., & Bridgewood, C. (2020). The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation-like syndrome. Autoimmunity Reviews. 2020;19(6):102537. doi:10.1016/j.autrev.2020.102537. https://doi.org/10.1016/j.autrev.2020.102537
2. Henderson, L. A., Canna, S. W., Friedman, K. G., et al. (2022). American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. Arthritis & Rheumatology. 2022;74(4):e1–e20. doi:10.1002/art.42062. Version 3. Arthritis & Rheumatology. https://doi.org/10.1002/art.42062
3. Colebatch-Bourn, A. N., Edwards, C. J., Collado, P., et al. (2015). EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Annals of the Rheumatic Diseases, 74, 1946–1957.
4. Consolaro, A., Ruperto, N., Bazso, A., et al. (2009). Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis & Rheumatism, 61(5), 658–666. https://doi.org/10.1002/art.24516
5. Petty, R. E., Southwood, T. R., Manners, P., et al. (2004). International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. The Journal of Rheumatology, 31(2), 390–392.
6. Ravelli A., Martini A. Juvenile idiopathic arthritis. The Lancet. 2007;369(9563):767–778. doi:10.1016/ S0140-6736(07)60363-8.
7. Wu, J., Shen, J., Han, Y., Qiao, Q., Dai, W., He, B., et al. (2021). Upregulated IL-6 indicates a poor COVID-19 prognosis: a call for tocilizumab and convalescent plasma treatment. Frontiers in Immunology. 2021;12:598799. doi:10.3389/fimmu.2021.598799. PMID: 33746945; PMCID: PMC7969719. a call for tocilizumab and convalescent plasma treatment. https://doi.org/10.3389/fimmu.2021.598799

